Cellectis Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Cellectis Contact Number

Contact Cellectis

6 hours ago Cellectis.com Show details

(651) 683-2803

Postcode (Optional) Country (Optional) Email Address *. Phone Number (Optional) Message *. I would like to receive information from the Cellectis Group by email. Legal Notice- …

1. 430 E 29th St, New York, NY 10016 · (651) 683-2803DIRECTIONSWEBSITE

Category: Cell Phone, Contact SupportShow more

Cellectis Company Contact Information Email, Phone

8 hours ago Adapt.io Show details

Get Cellectis company's verified contact number +1*****625, web address, revenue, total contacts 88, industry Healthcare, Pharmaceuticals, & Biotech and location at Adapt.io

Category: Cell Phone, Phone NumberShow more

Home Cellectis

6 hours ago Cellectis.com Show details

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq. Published on: March 29, 2021, 14:48 E.S.T. Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results. Published on: March 04, 2021, 14:59 E.S.T. …

Category: Cell Phone, Home PhoneShow more

Cellartis Crunchbase Company Profile & Funding

9 hours ago Crunchbase.com Show details

46 31 758

Contact Email [email protected]cellectis.com Phone Number 46 31 758 09 00 Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and …

Founded: 2001

Category: Cell PhoneShow more

FAQs Cellectis

3 hours ago Cellectis.com Show details

As of August 31, 2021, the number of shares constituting Cellectis’ capital is 45,465,310. As of the same date, the total number of voting rights is 51,067,217. How can I purchase Cellectis shares? To purchase Cellectis shares, you must have an account with a financial intermediary (bank, brokerage firm, online broker, etc.) and place your

Category: Cell PhoneShow more

Carmen Garcia Email, Phone Senior Accountant, Cellectis

1 hours ago Adapt.io Show details

Find Carmen Garcia's accurate email address and contact/phone number in Adapt.io. Currently working as Senior Accountant at Cellectis in New york, United States.

Category: Cell Phone, Phone NumberShow more

About Cellectis

4 hours ago Cellectis.com Show details

Cellectis has 21 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. This enables us to develop a new generation of immunotherapy product candidates with additional safety and efficacy attributes and equip them to resist mechanisms that inhibit immune system activity.

Category: Cell PhoneShow more

Cellectis Company Profile Office Locations, Competitors

6 hours ago Craft.co Show details

Cellectis has 272 employees across 4 locations and $33.72 M in annual revenue in FY 2017. See insights on Cellectis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Cell PhoneShow more

Contact Cellebrite

8 hours ago Cellebrite.com Show details

Contact. Get Started. Tapping into the Mind of a Digital Investigator - A Cellebrite Master Class Series – Watch on Demand! Contact Us. Discover how we can help transform your investigations today. General Sales Inquiry. Learn More. Learn More. General Support Ticket. …

Category: Cell Phone, Contact SupportShow more

Cellectis to Present Preclinical Data on UCARTMESO

5 hours ago Cellectis.com Show details

Poster Number: 143. Presenter: Roman Galetto, Ph.D, Director, Preclinical and Program Management. Date/Time: Friday November 12, 7:00AM - 8:30PM, Walter E. Washington Convention Center, Poster Hall (Hall E) Full text of the abstracts will be released on the SITC website at 7:00 a.m. ET on November 12, 2021.

Category: Cell PhoneShow more

Management Team Genespire

4 hours ago Genespire.com Show details

While at Cellectis, she has been leading the business development department, and has been instrumental in setting up transformational strategic partnerships with pharmaceutical companies. In her roles, she worked on a number of CGT programs, including autologous TCR T-cell therapies for cancer and ex vivo HSPC gene therapies for rare

Category: Contact NumberShow more

Cellectis to Present Preclinical Data on UCARTMESO

4 hours ago Globenewswire.com Show details

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology

Category: Cell PhoneShow more

Cellectis S.A Number of Employees 20152021 CLLS

9 hours ago Macrotrends.net Show details

Cellectis S.A number of employees from 2015 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Category: Cell PhoneShow more

Kuur Therapeutics Crunchbase Company Profile & Funding

1 hours ago Crunchbase.com Show details

44 20 7554

Legal Name Cell Medica Limited. Company Type For Profit. Contact Email [email protected] Phone Number 44 20 7554 4070. Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology

Category: Contact NumberShow more

Cellectis Provides Business Update and Reports Financial

1 hours ago Globenewswire.com Show details

877-407-3104

The call will include the Company’s second quarter results, and an update on business activities. The live dial-in information for the conference call is: US & Canada only: +1 877-407-3104

Category: Cell PhoneShow more

Monthly information on share capital and company voting rights

4 hours ago Ca.movies.yahoo.com Show details

Total number of voting rights. 08/31/2021. 45,465,310. 51,067,217. About Cellectis. Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat

Category: Contact NumberShow more

Cellectis to Present Preclinical Data on UCARTMESO

2 hours ago Biospace.com Show details

(646) 628 0300

For further information, please contact: Media contacts: Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300 Pascalyne Wilson, Director, Communications, +33776991433, [email protected]cellectis.com. Investor Relation contact: Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, [email protected]cellectis.com . Forward-looking Statements

Category: Cell PhoneShow more

Cellectis Completes Sale of $47 million through its ATM

1 hours ago Finance.yahoo.com Show details

646-628-0300

For further information, please contact: Media contacts: Margaret Gandolfo, 646-628-0300,Communications [email protected]cellectis.com or Conor McGlodrick, 914-355-0927,Zeno GroupConor

Category: Cell PhoneShow more

Monthly information on share capital and company voting rights

7 hours ago Finance.yahoo.com Show details

Date. Total number of shares in the capital. Total number of voting rights. 09/30/2021. 45,465,310. 51,066,417

Category: Contact NumberShow more

CELLECTIS (ALCLS.PA) Stock Price, News, Quote & History

Just Now Finance.yahoo.com Show details

Find the latest CELLECTIS (ALCLS.PA) stock quote, history, news and other vital information to help you with your stock trading and investing. Contact Us; U.S. markets closed FR0010425595

Category: Cell PhoneShow more

Cellectis to Present Preclinical Data on UCARTMESO

6 hours ago Stockhouse.com Show details

(646) 628 0300

For further information, please contact: Media contacts: Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300 Pascalyne Wilson, Director, Communications, +33776991433, [email protected]cellectis.com. Investor Relation contact: Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, [email protected]cellectis.com. Forward-looking Statements

Category: Cell PhoneShow more

Cellectis hiring Director Project Management in Raleigh

6 hours ago Linkedin.com Show details

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies to target and eradicate cancer cells. Contact info Email address

Category: Cell PhoneShow more

Cellectis to Present Preclinical Data on UCARTMESO

3 hours ago Benzinga.com Show details

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ:CLLS) (the "Company"), a gene-editing platform company with clinical-stage immuno-oncology programs using

Category: Cell PhoneShow more

Monthly information on share capital and company voting rights

Just Now Nz.finance.yahoo.com Show details

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube. For further information, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33776991433, media

Category: Contact NumberShow more

NC Commerce: Cancer Therapy Company Cellectis to Establish

Just Now Nccommerce.com Show details

Cellectis’ expansion in Wake County will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state’s Economic Investment Committee earlier today. Over the course of the 12-year term of this grant, the project will grow …

Category: Cell PhoneShow more

Cellectis, Harvard’s Wyss Institute to recode the human genome

1 hours ago Biospectrumasia.com Show details

Recode project will use Cellectis' TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies. Tuesday, 31 August 2021 Contact Number * +Country Code-Phone Number(xxx-xxxxxxx) Submit.

Category: Cell PhoneShow more

Cellectis S.A. (CLLS) Stock Price, News, Quote, Chart

Just Now Stockstelegraph.com Show details

Cellectis S.A. (CLLS) stock plummeted over -24.21% intraday to trade at $9.11 a share on NASDAQ. The stock opened with a loss of -15.89% at $10.11 and touched an intraday high of $10.11, declining 15.89% against the last close of $12.02. The stock went to a low of $9.05 during the session.

Category: Cell PhoneShow more

Monthly information on share capital and company voting rights

7 hours ago Ca.sports.yahoo.com Show details

Total number of voting rights. 09/30/2021. 45,465,310. 51,066,417. About Cellectis. Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat

Category: Contact NumberShow more

Cellectis S A : to Present PreClinical Data for CART

Just Now Marketscreener.com Show details

CELLECTIS S A: to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting - Form 6-K PU 10/12

Category: Cell PhoneShow more

Report of Foreign Issuer Pursuant to Rule 13a16 or 15d16

6 hours ago Ih.advfn.com Show details

81 69 16

Commission File Number: 001-36891. Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of principal executive office)

Category: Contact NumberShow more

Cellectis hiring Manufacturing Operations Associate II in

6 hours ago Linkedin.com Show details

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies to target and eradicate cancer cells. Contact info Email address

Category: Cell PhoneShow more

Monthly information on share capital and company voting rights

Just Now Au.finance.yahoo.com Show details

Total number of shares. in the capital. Total number of voting rights. 06/30/2021. 45,461,310. 51,531,339. About Cellectis. Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to

Category: Contact NumberShow more

Study Evaluating Safety and Efficacy of UCART Targeting

7 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04142619

Category: Contact NumberShow more

CLLS Short Interest Ratio and Volume (Cellectis) MarketBeat

1 hours ago Marketbeat.com Show details

Cellectis saw a drop in short interest in August. As of August 31st, there was short interest totaling 1,250,000 shares, a drop of 3.8% from the previous total of 1,300,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline

Category: Cell PhoneShow more

Should You Accumulate Cellectis SA (CLLS) Stock Monday

2 hours ago Investorsobserver.com Show details

Cellectis SA has a Long-Term Technical rank of 6. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 94% of the market scoring higher. In the Biotechnology industry which is number 136 by this metric, CLLS ranks better than 18% of stocks. Important Dates for Investors in CLLS:

Category: Cell PhoneShow more

Monthly information on share capital and company voting

4 hours ago Globenewswire.com Show details

in the capital. Total number of voting rights. 08/31/2021. 45,465,310. 51,067,217. About Cellectis. Cellectis is a gene editing company, developing first of its kind therapeutic products

Category: Contact NumberShow more

Monthly information on share capital and company voting rights

Just Now Nz.finance.yahoo.com Show details

646-385-9008

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube. TALEN ® is a registered trademark owned by Cellectis. For further information, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33776991433, [email protected]cellectis.com. IR contact: Simon Harnest, Chief Investment Officer, 646-385-9008, simon.harnest

Category: Contact NumberShow more

Monthly information on share capital and company voting rights

Just Now Ca.finance.yahoo.com Show details

646-385-9008

For further information, please contact: Media contacts:Pascalyne Wilson, Communications Manager, +33776991433, [email protected]cellectis.com IR contact:Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, [email protected]cellectis.com Attachment Voting_Rights_PR_April_EN_docx

Category: Contact NumberShow more

Monthly information on share capital and company voting

4 hours ago Globenewswire.com Show details

Total number of shares in the capital: Total number of voting please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33776991433, [email protected]cellectis.com. IR …

Category: Contact NumberShow more

CELLECTIS S.A. : Shareholders Board Members Managers and

1 hours ago Marketscreener.com Show details

Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Category: Cell PhoneShow more

Monthly information on share capital and company voting rights

Just Now Nz.finance.yahoo.com Show details

646-385-9008

For further information, please contact: Media contacts:Pascalyne Wilson, Communications Manager, +33776991433, [email protected]cellectis.com IR contact:Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, [email protected]cellectis.com Attachment Voting_Rights_PR_Feb_EN_docx

Category: Contact NumberShow more

Andrew Garton Director, Translational Sciences

9 hours ago Linkedin.com Show details

Andrew and I worked together on a number of development projects during our years at OSI and on a complex out-licensing project that required Andrew to recreate a large number of reports for the

Title: Director, Translational Sciences at …
Location: New York, New York
Connections: 471

Category: Contact NumberShow more

Cellectis Inc.: Monthly information on share capital and

8 hours ago Bloomberg.com Show details

917-580-1088

For further information, please contact: Media contacts: Jennifer Moore, SVP, Public Relations & NY Site Head 917-580-1088, [email protected]cellectis.com IR contact: Simon Harnest, SVP, Corporate Strategy

Category: Cell PhoneShow more

Cellectis S.A. (CLLS): The stock short term indicators are

5 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 44.16 million. CLLS does have institutional investors; and they hold 39.50% of the stock. Cellectis S.A. – Insider Activity and Holdings. Currently, the stock has been recommended as Strong Buy by 11 of the brokerage firms.

Category: Cell PhoneShow more

Cellectis to Present Preclinical Data on UCARTMESO

Just Now Finance.yahoo.com Show details

For more information, visit www.cellectis.com Follow Cellectis on social media: @cellectis, LinkedIn and YouTube. For further information, please contact: Media contacts:

Category: Cell PhoneShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

Where can i find cellectis on the market?

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.TALEN® is a registered trademark owned by Cellectis.

What are the rights and responsibilities of cellectis?

Cellectis expects its associates, as well as its providers and subcontractors, to comply with this Charter in execution of their activities on a daily basis. They are also expected to respect human rights, labor rights, and the environment. For more information on any story, or for press enquiries, get in touch with our Media Team.

Why is cellectis a off the sh stock?

Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-sh Stocks can flirt with a price bottom for a lot of reasons. Usually, however, investors will assume that there is something fundamentally unsound about the stock, or the company.

How is cellectis used in off the shelf therapies?

Cellectis gene-edits “Chimeric Antigen Receptor” (CAR) T-cells from healthy donors into “off-the-shelf” immunotherapy product candidates that are designed to work for the largest number of patients. It’s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made.

Brand New Updated

Popular Brands

Costco
Cisco
Ccu
Cae